Baclofen for narcolepsy with cataplexy: two cases
Elliott Kyung Lee,1,2 Alan Bruce Douglass1,2 1Department of Psychiatry, Faculty of Medicine, Institute of Mental Health Research, University of Ottawa, 2Royal Ottawa Mental Health Center, Ottawa, ON, Canada Abstract: Narcolepsy is a disabling sleep disorder characterized by daytime hypersomnolence....
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e60548a9c2174708ab410a22336759ea |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Elliott Kyung Lee,1,2 Alan Bruce Douglass1,2 1Department of Psychiatry, Faculty of Medicine, Institute of Mental Health Research, University of Ottawa, 2Royal Ottawa Mental Health Center, Ottawa, ON, Canada Abstract: Narcolepsy is a disabling sleep disorder characterized by daytime hypersomnolence. Those with cataplexy have spells of muscle weakness precipitated by strong emotions, especially laughter or surprise. Cataplexy treatments include antidepressants or a GABA-B agonist, gamma hydroxybutyrate (GHB). GHB is the most effective treatment for cataplexy, but is expensive and can have significant side effects. A recent report of a murine model of narcolepsy-cataplexy suggests R-baclofen has potential efficacy against cataplexy. We report on two narcolepsy patients with multiple daily cataplexy episodes, one of whom had been effectively treated with GHB, but had to discontinue it for unrelated medical reasons. Both subsequently tried baclofen and experienced almost complete resolution of cataplexy. This report suggests baclofen can be an effective treatment for cataplexy in humans and warrants further study. Keywords: hypersomnolence, gamma hydroxybutyrate, excessive daytime sleepiness |
|---|